{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"The overall survival or survival time is defined as the time from registration to death due to any cause. The distribution of overall survival will be estimated using the method of Kaplan-Meier.","groups":[{"description":"Patients receive anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody (MDX-010) IV over 90 minutes on day 1. Treatment repeats every 28 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"MDX-010"}],"populationDescription":"No participants proceeded to Phase 2 for evaluation.","reportingStatus":"POSTED","timeFrame":"From registration to death (up to 2 years)","title":"Overall Survival (Phase 2)","type":"SECONDARY"}